自己増幅RNA（saRNA）合成市場- 世界の産業規模、シェア、動向、機会、予測、製品・サービス別、用途別、エンドユーザー別、地域別セグメント、競合、2020年～2030年

世界の自己増幅RNA（saRNA）合成市場は、2024年に1億969万米ドルと評価され、2030年にはCAGR 19.33%を記録して3億1,712万米ドルに達すると予測されています。

saRNAは、宿主細胞内で自己複製する能力により、大幅に少ない投与量で高タンパク質発現を可能にすることで、従来のmRNAに決定的な優位性を提供しています。この効率性により、感染症、腫瘍学、希少遺伝性疾患などの治療分野での利用が進んでいます。

saRNAは、治療効果が長期間持続し、必要な材料が少ないことから、ワクチン開発、遺伝子治療、がん免疫療法に特に魅力的な技術です。CDMOや製薬会社からの投資により、スケーラブルで高精度の合成プラットフォームへの需要が高まっています。RNAに特化したバイオテクノロジー企業と研究機関の共同研究は、技術革新をさらに加速させています。年間127万人以上が死亡していると推定される抗菌薬耐性の世界の重荷を考えると、saRNAは次世代ワクチンや治療ソリューションに大きな期待を寄せており、将来のヘルスケア用途における戦略的重要性を強調しています。

市場促進要因

次世代RNA治療薬およびワクチンに対する需要の急増

主な市場課題

合成プロトコルの標準化の欠如

主な市場動向

モジュール式およびプラグアンドプレイ・プラットフォーム開発

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の自己増幅RNA（saRNA）合成市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品・サービス別（製品（既製saRNA、酵素・試薬、その他）、カスタム合成サービス）
  • 用途別（治療薬開発（感染症、腫瘍学、その他）、生物医学調査）
  • エンドユーザー別（製薬・バイオテクノロジー企業、学術・研究機関、その他）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米の自己増幅RNA（saRNA）合成市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の自己増幅RNA（saRNA）合成市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の自己増幅RNA（saRNA）合成市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の自己増幅RNA（saRNA）合成市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの自己増幅RNA（saRNA）合成市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• GenScript Biotech Corporation
• Creative Biogene, Inc.
• OZ Biosciences SAS
• BOC Sciences
• Croyez Bioscience Co., Ltd.
• Creative Biolabs, Inc.
• Maravai LifeSciences Holdings, Inc.
• Areterna LLC
• Applied DNA Sciences, Inc.
• Moderna, Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Self-amplifying RNA (saRNA) Synthesis Market was valued at USD 109.69 million in 2024 and is projected to reach USD 317.12 million by 2030, registering a CAGR of 19.33%. This market is experiencing rapid growth as the pharmaceutical and biotechnology industries increasingly adopt next-generation RNA technologies. saRNA provides a critical advantage over conventional mRNA by enabling high protein expression at significantly lower doses due to its ability to self-replicate within host cells. This efficiency is driving its use in therapeutic areas such as infectious disease, oncology, and rare genetic disorders.

The technology's long-lasting therapeutic effects, combined with its lower material requirements, make saRNA especially attractive for vaccine development, gene therapies, and cancer immunotherapy. Investment from CDMOs and pharmaceutical firms is fueling demand for scalable and high-precision synthesis platforms. Collaborations between RNA-focused biotech companies and research institutions are further accelerating innovation. Given the global burden of antimicrobial resistance-estimated to cause over 1.27 million deaths annually-saRNA holds significant promise for next-generation vaccines and treatment solutions, underscoring its strategic importance in future healthcare applications.

Key Market Drivers

Surging Demand for Next-Generation RNA Therapeutics and Vaccines

A major driver of the saRNA synthesis market is the rising demand for advanced RNA-based therapeutics and vaccines. saRNA's self-amplifying mechanism allows for greater protein production using smaller doses than traditional mRNA, reducing overall production costs while improving therapeutic efficacy. This is particularly beneficial in high-priority therapeutic fields such as infectious diseases, rare disorders, and oncology.

The proven success of RNA technologies in clinical settings has strengthened industry confidence and prompted greater integration of saRNA into commercial pipelines. As biopharma companies seek more cost-efficient and potent treatment platforms, saRNA's unique attributes position it as a transformative tool in the future of medicine.

Key Market Challenges

Lack of Standardization in Synthesis Protocols

The absence of standardized protocols is a key challenge impacting the scalability and reproducibility of saRNA production. saRNA molecules are more complex and larger than conventional mRNA, requiring meticulous optimization of synthesis parameters such as capping, dsRNA reduction, and purification techniques.

Inconsistent practices across labs and CDMOs-due to reliance on proprietary processes and varying reagent quality-result in variability in product quality. This variability poses risks during clinical development and limits the ability to establish uniform manufacturing practices across the industry, especially when scaling from research-grade to clinical-grade production.

Key Market Trends

Modular and Plug-and-Play Platform Development

A significant trend shaping the saRNA synthesis market is the advancement of modular and plug-and-play development platforms. These systems are engineered to streamline the design, production, and scalability of saRNA constructs by enabling rapid interchange of functional elements-such as replicase sequences, antigen regions, untranslated regions (UTRs), and capping mechanisms-without needing to alter the core RNA structure.

This flexibility accelerates the development cycle, supports swift adaptation to emerging pathogens or mutations, and enhances efficiency in therapeutic discovery. Such platforms are particularly valuable in addressing rapidly evolving disease targets and are instrumental in improving responsiveness during public health emergencies.

Key Market Players

• GenScript Biotech Corporation
• Creative Biogene, Inc.
• OZ Biosciences SAS
• BOC Sciences
• Croyez Bioscience Co., Ltd.
• Creative Biolabs, Inc.
• Maravai LifeSciences Holdings, Inc.
• Areterna LLC
• Applied DNA Sciences, Inc.
• Moderna, Inc.

Report Scope:

In this report, the Global Self-amplifying RNA Synthesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Self-amplifying RNA Synthesis Market, By Product & Service:

• Products
  • Premade saRNA
  • Enzymes & Reagents
  • Others
• Custom Synthesis Services

Self-amplifying RNA Synthesis Market, By Application:

• Therapeutics Development
  • Infectious Diseases
  • Oncology
  • Others
• Biomedical Research

Self-amplifying RNA Synthesis Market, By End User:

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Others

Self-amplifying RNA Synthesis Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Self-amplifying RNA Synthesis Market.

Available Customizations:

Global Self-amplifying RNA Synthesis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Self-amplifying RNA Synthesis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product & Service (Products {Premade saRNA, Enzymes & Reagents, Others}, Custom Synthesis Services)
  • 5.2.2. By Application (Therapeutics Development {Infectious Diseases, Oncology, Others}, Biomedical Research)
  • 5.2.3. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Self-amplifying RNA Synthesis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product & Service
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Self-amplifying RNA Synthesis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product & Service
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Mexico Self-amplifying RNA Synthesis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product & Service
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Canada Self-amplifying RNA Synthesis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product & Service
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Self-amplifying RNA Synthesis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product & Service
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Self-amplifying RNA Synthesis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product & Service
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Self-amplifying RNA Synthesis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product & Service
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Self-amplifying RNA Synthesis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product & Service
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Self-amplifying RNA Synthesis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product & Service
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Self-amplifying RNA Synthesis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product & Service
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Self-amplifying RNA Synthesis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product & Service
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Self-amplifying RNA Synthesis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product & Service
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Self-amplifying RNA Synthesis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product & Service
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. South Korea Self-amplifying RNA Synthesis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product & Service
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. Japan Self-amplifying RNA Synthesis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product & Service
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Self-amplifying RNA Synthesis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product & Service
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Self-amplifying RNA Synthesis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product & Service
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Self-amplifying RNA Synthesis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product & Service
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Self-amplifying RNA Synthesis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product & Service
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Self-amplifying RNA Synthesis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product & Service
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Self-amplifying RNA Synthesis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product & Service
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Self-amplifying RNA Synthesis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product & Service
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Self-amplifying RNA Synthesis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product & Service
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Self-amplifying RNA Synthesis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product & Service
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. GenScript Biotech Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Creative Biogene, Inc.
• 15.3. OZ Biosciences SAS
• 15.4. BOC Sciences
• 15.5. Croyez Bioscience Co., Ltd.
• 15.6. Creative Biolabs, Inc.
• 15.7. Maravai LifeSciences Holdings, Inc.
• 15.8. Areterna LLC
• 15.9. Applied DNA Sciences, Inc.
• 15.10. Moderna, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer